Estrella Immunopharma, Inc. (NASDAQ:ESLA) Short Interest Up 158.2% in November

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the recipient of a significant growth in short interest in November. As of November 30th, there was short interest totalling 37,700 shares, a growth of 158.2% from the November 15th total of 14,600 shares. Based on an average daily volume of 137,400 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.4% of the shares of the stock are sold short.

Estrella Immunopharma Stock Performance

Shares of NASDAQ:ESLA traded up $0.01 during midday trading on Wednesday, hitting $1.38. The company’s stock had a trading volume of 163,829 shares, compared to its average volume of 76,462. The company has a market cap of $49.93 million, a P/E ratio of -5.31 and a beta of 0.46. Estrella Immunopharma has a 12-month low of $0.63 and a 12-month high of $3.23. The business’s 50 day simple moving average is $0.95 and its 200 day simple moving average is $1.10.

Estrella Immunopharma (NASDAQ:ESLA) last posted its quarterly earnings results on Friday, September 27th. The company reported ($0.13) EPS for the quarter.

Estrella Immunopharma Company Profile

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.